SurgiSTUD Launches a New Orthopedic Subdivision in their STUD Catalog

SurgiSTUD (STUD is an acronym for Surgical Training Utility Device), announced it’s launching a new orthopedic subdivision in their STUD catalog. These STUDs are surgical training models with superior biomechanical fidelity, customizability, and cost-savings over existing cadaveric and synthetic training options.

The addition of the orthopedic models to their catalog, including knee, hip, shoulder, and foot models, provides a needed, alternate solution to expensive cadavers that are currently used in the training of orthopedic surgeons.

What this means:

  • Customers have a consistent and repeatable training platform that can be delivered across the globe.
  • Customers can increase the number of training sessions while reducing the overall economic spend.
  • Customers no longer have to delay training or medical education due to cadaver shortages.
  • Customers can order customized models that can improve medical training by mimicking specified pathology and deformities they are training for.
  • Training can be conducted in places beyond a lab as all models are synthetic.

“We are happy to expand our catalog of STUDs to include orthopedics. We understand the need for cost-effective and consistent training models and made it our mission to find a solution that can provide medical professionals and R&D teams a safer and more affordable approach to medical education while maintaining the same educational experience as traditional cadavers.” – John Brambert, Executive Vice President SurgiSTUD.

As the medical industry experiences delays, cancellations, and rising costs due to cadaver shortages, SurgiSTUD is continuing to step up to provide surgical training and utility devices that provide a superior platform that will now cover orthopedics along with their spine devices.

SourceSurgiSTUD

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”